PD-1 Inhibitor Combined with Radiotherapy and GM-CSF with or not IL-2 (PRaG regimen) in Patients with Microsatellite Stable Metastatic Colorectal Cancer

被引：0
|
作者：
Yang, J. [1 ]
Xing, P. [1 ]
Kong, Y. [1 ]
Xu, M. [1 ]
Zhang, L. [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 2, Dept Radiotherapy & Oncol, Suzhou, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2341
引用
收藏
页码：E154 / E154
页数：1
相关论文
共 50 条
  • [31] Clinical outcome and safety in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab
    Halama, Niels
    Pruefer, Ulrike
    Froemming, Anna
    Beyer, Diana
    Eulberg, Dirk
    Jungnelius, Jarl Ulf
    Mangasarian, Aram
    CANCER RESEARCH, 2019, 79 (13)
  • [32] Safety and clinical outcome in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab
    Halama, N.
    Pruefer, U.
    Froemming, A.
    Beyer, D.
    Eulberg, D.
    Jungnelius, J.
    Mangasarian, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer
    Shi, Xiaojun
    Zhang, Xinji
    Li, Jinlong
    Guo, Fangfang
    Hu, Zhiming
    Jing, Yuming
    Bai, Li
    Chen, Sansan
    Wan, Pei
    Wang, Fei
    Gao, Jimin
    Tan, Wanlong
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (06) : 883 - 893
  • [34] Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report
    Liu, Zhuixing
    Wang, Fang
    Zhang, Yingqi
    Lu, Jun
    Yang, Yang
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [35] Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
    Verra, N
    Jansen, R
    Groenewegen, G
    Mallo, H
    Kersten, MJ
    Bex, A
    Vyth-Dreese, FA
    Sein, J
    van de Kasteele, W
    Nooijen, WJ
    de Waal, M
    Horenblas, S
    de Gast, GC
    BRITISH JOURNAL OF CANCER, 2003, 88 (09) : 1346 - 1351
  • [36] Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
    N Verra
    R Jansen
    G Groenewegen
    H Mallo
    M J Kersten
    A Bex
    F A Vyth-Dreese
    J Sein
    W van de Kasteele
    W J Nooijen
    M de Waal
    S Horenblas
    G C de Gast
    British Journal of Cancer, 2003, 88 : 1346 - 1351
  • [37] Cytokines IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel
    Penson, RT
    Kronish, K
    Duan, Z
    Feller, AJ
    Stark, P
    Cook, SE
    Duska, LR
    Fuller, AF
    Goodman, AK
    Nikrui, N
    MacNeill, KM
    Matulonis, UA
    Preffer, FI
    Seiden, MV
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2000, 10 (01) : 33 - 41
  • [38] The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
    Pietrantonio, Filippo
    Morano, Federica
    Niger, Monica
    Ghelardi, Filippo
    Chiodoni, Claudia
    Palazzo, Michele
    Nichetti, Federico
    Manca, Paolo
    Cristarella, Eleonora
    Doldi, Valentina
    Zaffaroni, Nadia
    Sabella, Giovanna
    Brambilla, Nadia
    Benincasa, Elena
    Giacovelli, Giampaolo
    Vitalini, Cristina
    Girolami, Federica
    Rovati, Lucio C.
    CLINICAL CANCER RESEARCH, 2025, 31 (04) : 649 - 658
  • [39] A phase II trial of stamp V (CTCb) with IL-2 plus G-CSF primed PBSC and IL-2 plus GM-CSF post ABMT for advanced breast cancer patients.
    Harrison, JS
    Bayer, RA
    Malhotra, D
    Wolin, M
    Stiff, PS
    BLOOD, 1999, 94 (10) : 352A - 352A
  • [40] DEEP, DURABLE RESPONSE TO PD-1 INHIBITOR MONOTHERAPY IN MICROSATELLITE-STABLE, TUMOR MUTATIONAL BURDEN-HIGH COLORECTAL CANCER
    Schellenberg, Samuel
    Kim, Leeseul
    Chae, Young Kwang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A661 - A661
12345